Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher to Sell Microbiology Business to Astorg
Thermo Fisher Scientific has struck a deal to sell its microbiology business to European private-equity firm Astorg for about $1.075 billion.
Thermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities
Thermo Fisher Scientific experienced a sharp post-Q1 selloff despite beating sales and EPS expectations and raising full-year guidance. Inorganic growth from recent acquisitions, notably Clario, contributed materially to raised EPS guidance and overall revenue outlook. Short-term headwinds in government/academic spending and diagnostics are not expected to derail Thermo's long-term growth strategy, supported by reshoring and AI adoption.
Thermo Fisher Scientific Inc. (TMO) Q1 2026 Earnings Call Transcript
Thermo Fisher Scientific Inc. (TMO) Q1 2026 Earnings Call Transcript
Thermo Fisher falls after earnings top estimates, but growth concerns persist
Shares of Thermo Fisher Scientific Inc (NYSE:TMO, XETRA:TN8) were down more than 7.5% on Thursday after investors weighed a stronger-than-expected quarterly profit against muted underlying growth and a still-cautious outlook despite an upgraded full-year revenue forecast. The life sciences tools and services company reported adjusted earnings per share of $5.44 for the first quarter of fiscal 2026, beating analyst expectations of $5.25.
TMO Q1 Earnings & Revenues Top Estimates, Stock Down in Pre-Market
TMO beats Q1 EPS and revenue estimates with steady growth, yet shares slip 4% in pre-market after results and mixed segment performance.
Thermo Fisher (TMO) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Thermo Fisher Scientific (TMO) Q1 Earnings and Revenues Top Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.44 per share, beating the Zacks Consensus Estimate of $5.2 per share. This compares to earnings of $5.15 per share a year ago.
Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
Thermo Fisher Scientific on Thursday reported first-quarter profit and revenue above Wall Street estimates, as growth in its laboratory products and biopharma services business helped offset softness in analytical instruments and specialty diagnostics.
Caprock Group LLC Acquires 1,804 Shares of Thermo Fisher Scientific Inc. $TMO
Caprock Group LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 21.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,304 shares of the medical research company's stock after acquiring an additional
Boston Trust Walden Corp Buys 3,873 Shares of Thermo Fisher Scientific Inc. $TMO
Boston Trust Walden Corp lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 9.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,973 shares of the medical research company's stock after purchasing an additional
Thermo Fisher: Great Business Still Trading At A Risky Price Before Earnings
Thermo Fisher Scientific (TMO) remains a high-quality, stable business, but its stock is currently overvalued relative to its growth outlook. TMO reported FY25 revenue growth of 3.9% and EPS growth of 7.3%, with management guiding for 6–8% adjusted EPS growth in FY26. Despite solid fundamentals and resilient end-markets, valuation multiples near 30x earnings/free cash flow appear stretched unless double-digit growth resumes.
Unlocking Q1 Potential of Thermo Fisher (TMO): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
